A Study of LY3041658 in Adults With Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

March 15, 2022

Study Completion Date

October 13, 2022

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Placebo

Administered IV

DRUG

LY3041658

Administered IV

Trial Locations (20)

2010

Holdsworth House Medical Practice, Sydney

2152

Westmead Hospital, Northmead

4575

Sunshine Coast University Hospital, Birtinya

6160

Fremantle Dermatology, Fremantle

27710

Duke University Medical Center, Durham

30060

Marietta Dermatology Clinical Research, Marietta

30328

Advanced Medical Research, Sandy Springs

33021

Skin Care Research, Inc, Hollywood

33125

Nova Clinical Research, LLC, Miami

44106

University Hospitals Case Medical Center, Cleveland

45267

UC Physicians Office Dermatology, Cincinnati

63110

Washington University School of Medicine, St Louis

72758

Northwest Arkansas Clinical Trials Center, Rogers

90045

Dermatology Research Associates, Los Angeles

92708

First OC Dermatology, Fountain Valley

33613-1244

ForCare Clinical Research, Tampa

01915

Allcutis Research, Inc., Beverly

02215

Beth Israel Deaconess Medical Center, Boston

03801

ALLCUTIS Research, Portsmouth

03050

The Royal Melbourne Hospital, Parkville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04493502 - A Study of LY3041658 in Adults With Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter